AstraZeneca and Daiichi Sankyo are preparing regulatory filings that could make their HER2-directed antibody-drug conjugate (ADC) Enhertu an option for previously untreated breast cancer for the first ...
60+ years, thousands of cars, hundreds of tests—we've done the work for you.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果